Spearhead Bio Raises $1.6M to Scale Gene-Editing Platform That Sidesteps CRISPR's Biggest Weakness
A St. Louis startup that promises to solve one of CRISPR's most frustrating limitations has closed a $1.62 million seed round, bringing in enough capital to push its unconventional gene-editing technology deeper into commercial agriculture.
Spearhead Bio announced Tuesday that BioGenerator Ventures and Danforth Technology Company co-led the oversubscribed financing, joined by QRM Capital, Grit Road Partners, St. Louis County Port Authority Helix Fund and SDH Capital. The company structured the deal as a SAFE and declined to name the valuation, though Chief Scientific Officer Keith Slotkin told St. Louis Magazine the money gives the team "runway for another year and a half to two years."
It's the second outside capital raise for Spearhead, which closed an undisclosed SAFE last year. Founded in 2024 and spun out of the Donald Danforth Plant Science Center in February 2025, the company has spent the intervening months pitching a pitch a bold claim: that its platform can do what CRISPR famously struggles with.
Precision Without the Chaos
CRISPR has revolutionized genetics by making DNA cutting cheap and reliable. Insertion, though, remains messier. When researchers try to drop large genetic sequences into a genome, the edits often land in the wrong place, scrambling genes and complicating downstream breeding work. For crop developers chasing complex traits, that randomness translates into years of delay and regulatory headaches.
Spearhead's answer is a platform called TAHITI (Transposase Assisted Homology Independent Targeted Insertion), which combines transposable element machinery with Cas9 or Cas12a proteins. The result, according to the company, is a system that can "glue" sizable DNA payloads precisely where CRISPR makes its cuts.
"TAHITI saves our partners years of development time and millions of dollars," Slotkin said, though the startup has yet to disclose which partners are paying for licenses or how far those collaborations have progressed.
The science underpinning the platform appeared in Nature last June, with Slotkin as first author. That paper demonstrated targeted insertion in Arabidopsis and soybean, work that originated at Danforth before the spinout. Spearhead has since filed for patent protection on the method, according to company statements.
Five Edits, Multiple Crops
The platform enables what Spearhead describes as five distinct classes of genetic manipulation: replacing, inserting, copying, rearranging and stacking large DNA sequences in plant genomes. Internally, researchers at the Danforth Center have reported early success applying TAHITI to cassava, a staple crop in tropical regions. The company is also working on soybean and corn through industry licenses it has not named publicly.
One advantage Spearhead emphasizes is regulatory optionality. Depending on how the edits are designed, TAHITI could fit into either transgenic or non-transgenic development pathways, potentially shortening approval timelines in certain jurisdictions. Whether regulators will accept that framing remains to be seen.
The startup recently secured a Phase I STTR grant from the National Science Foundation to accelerate TAHITI applications in corn, a project valued at roughly $305,000, according to AgTechNavigator. It's the kind of non-dilutive funding that stretches runway for an early-stage biotech, though the real test will be converting pilot collaborations into revenue.
The Team and What Comes Next
Slotkin, who also holds positions as Vice President of Commercialization at the Danforth Center and Professor at the University of Missouri-Columbia, founded Spearhead and remains its scientific lead. Mike Bielski serves as CEO. Yu-Hung Hung, a co-author on the Nature paper, is Principal Investigator. The company's scientific advisory board includes Larry Gilbertson, a veteran of Monsanto and Bayer, along with Jerry Hjelle, Jon Lightner (former VP of Biotech at Pioneer Hi-Bred) and Nathan Hancock. LinkedIn pegs the headcount at somewhere between two and ten employees.
Danforth Technology Company, the commercialization arm of the Danforth Plant Science Center, incubated the startup and chipped in as a co-lead investor. BioGenerator Ventures, a local life sciences fund with a history of backing St. Louis-area biotechs, anchored the round.
Bielski told AgFunder News that Spearhead is "not just another CRISPR company," a line that reflects both ambition and the crowded field the startup is entering. The company says it's in active discussions with unnamed partners and has secured multiple TAHITI licenses, though specifics remain under wraps.
For now, the capital buys time to prove the technology works beyond academic proof-of-concept. Expanding the crop portfolio and deepening industry partnerships are the stated priorities. Whether TAHITI can deliver on its promise to "fundamentally change genome engineering in agriculture," as Bielski put it, will depend on how well those first commercial edits perform in the field.
